Benefits Overview Enrollment & Participation Engagement & Persistence Clinical Outcomes Clinical Pathway Medical Utilization Program Performance Member Experience Engagement & Outcomes

AT&T · GLP-1 & Optimization

Clinical Pathway & Optimization

The GLP-1 patient journey from prescription through 12-month outcomes, with optimization levers and care team interventions.

Sample dataObserved

GLP-1 therapy pathway

30,000

Eligible

2,000

Enrolled

1,766

Baseline complete

88%

1,678

Started therapy

95%

1,524

90-day active

91%

1,326

6-month persistent

87%

1,158

12-month outcomes

87%

1,009

Measurable improvement

87%

Funnel from 30,000 eligible to 1,009 with measurable improvement. Persistence rates: 90-day 1,524 → 6-month 1,326 → 12-month 1,158.

Clinical outcomes at current period

Measured

61%

Weight loss ≥5%

n = 1,285

45% benchmark

Measured

-9.9%

Avg weight change

from baseline

-5.2% benchmark

Measured

8 mmHg

Systolic BP drop

average reduction

4 mmHg benchmark

Measured

0.5%

HbA1c reduction

average reduction

0.3% benchmark

BMI change

Average BMI

33.8 → 30.5

among 643 members with paired measurements

Follow-up measurement coverage

Weight

638/83976%

Blood pressure

579/83969%

HbA1c

403/83948%

Lipids

445/83953%

Optimization levers

Dosage titration

82% at target dose

Of active members, 82% have reached the recommended maintenance dose. 18% are still titrating — monitored weekly by the care team.

Check-in cadence

2.8 actions/week

Active members average 2.8 meaningful actions per week (check-ins, messages, refills). Members below 1.5/week are flagged for outreach.

Discontinuation management

64 discontinued (7.6%)

Side effects (31%), cost/coverage (22%), and refill difficulties (16%) are the top reasons. Proactive outreach recovers ~30% of at-risk members.

Clinical monitoring

76% weight · 48% A1c

Follow-up measurement coverage varies by metric. Weight is well-captured; A1c and lipid gaps are addressed through lab partnerships.

Discontinuation analysis

64 members discontinued (3.8% of started). Top reasons and mitigation strategies:

Side effects

2031%Dose adjustment, alternative GLP-1, supportive care

Cost / coverage

1422%Benefits verification, patient assistance program

Refill difficulties

1016%Pharmacy coordination, auto-refill enrollment

Clinical decision

813%Care team review, alternative therapy

Other / unknown

1219%Outreach and root-cause analysis

All outcomes are measured from paired baseline and follow-up values. Benchmarks are illustrative, not validated external data. Clinical outcomes are shown only in properly aggregated, privacy-safe form.

Employee Privacy Protected by Design

Employer reporting is designed to present aggregate workforce and health-program insights without exposing individual clinical records. Small-group reporting restrictions help reduce the risk of employee identification.

Sample dataPrivacy-restricted reporting

Aggregated information is not described as HIPAA-de-identified unless applicable de-identification requirements have been satisfied and verified.